Windtree Therapeutics Faces Potential Nasdaq Delisting Due to Bid Price Deficiency

Reuters

2025/06/21

Windtree <a href="https://laohu8.com/S/LENZ">Therapeutics</a> Faces Potential Nasdaq Delisting Due to Bid Price Deficiency

Windtree Therapeutics Inc. has announced receiving a deficiency letter from the Nasdaq Listing Qualifications Department regarding its failure to meet the minimum bid price requirement for continued listing on the Nasdaq Capital Market. For the past 30 consecutive business days, the company's common stock has closed below the required $1.00 per share threshold. While companies typically have 180 days to rectify such deficiencies, Windtree is under a Discretionary Panel Monitor until March 2026. This situation arises as the company has conducted two reverse stock splits in the last two years, totaling a ratio of over 250 to one. Windtree plans to request a hearing before a Nasdaq Hearings Panel by June 25, 2025, which will temporarily stay any suspension or delisting actions. However, there is no guarantee that the company will be granted an extension or regain compliance. Currently, Windtree's stock continues to trade under the symbol "WINT."

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Windtree Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001437749-25-020949), on June 20, 2025, and is solely responsible for the information contained therein.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2545849103"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2545849103\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2545849103?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-06-21 05:21","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2545849103","market":"fut","top_or_hot":-1,"title":"Windtree Therapeutics Faces Potential Nasdaq Delisting Due to Bid Price Deficiency","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Windtree <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Faces Potential Nasdaq Delisting Due to Bid Price Deficiency\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Windtree Therapeutics Inc. has announced receiving a deficiency letter from the Nasdaq Listing Qualifications Department regarding its failure to meet the minimum bid price requirement for continued listing on the Nasdaq Capital Market. For the past 30 consecutive business days, the company's common stock has closed below the required $1.00 per share threshold. While companies typically have 180 days to rectify such deficiencies, Windtree is under a Discretionary Panel Monitor until March 2026. This situation arises as the company has conducted two reverse stock splits in the last two years, totaling a ratio of over 250 to one. Windtree plans to request a hearing before a Nasdaq Hearings Panel by June 25, 2025, which will temporarily stay any suspension or delisting actions. However, there is no guarantee that the company will be granted an extension or regain compliance. Currently, Windtree's stock continues to trade under the symbol \"WINT.\"\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Windtree Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001437749-25-020949), on June 20, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Windtree Therapeutics Faces Potential Nasdaq Delisting Due to Bid Price Deficiency</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWindtree Therapeutics Faces Potential Nasdaq Delisting Due to Bid Price Deficiency\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-06-21 05:21</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Windtree <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Faces Potential Nasdaq Delisting Due to Bid Price Deficiency\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Windtree Therapeutics Inc. has announced receiving a deficiency letter from the Nasdaq Listing Qualifications Department regarding its failure to meet the minimum bid price requirement for continued listing on the Nasdaq Capital Market. For the past 30 consecutive business days, the company's common stock has closed below the required $1.00 per share threshold. While companies typically have 180 days to rectify such deficiencies, Windtree is under a Discretionary Panel Monitor until March 2026. This situation arises as the company has conducted two reverse stock splits in the last two years, totaling a ratio of over 250 to one. Windtree plans to request a hearing before a Nasdaq Hearings Panel by June 25, 2025, which will temporarily stay any suspension or delisting actions. However, there is no guarantee that the company will be granted an extension or regain compliance. Currently, Windtree's stock continues to trade under the symbol \"WINT.\"\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Windtree Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001437749-25-020949), on June 20, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"WINT","symbol_name":"Windtree Therapeutics, Inc.","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250620:nNDL5pYbtB:1","article_id":"2545849103","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2545849103","pubTimestamp":1750454464,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Windtree Therapeutics Inc. has announced receiving a deficiency letter from the Nasdaq Listing Qualifications Department regarding its failure to meet the minimum bid price requirement for continued listing on the Nasdaq Capital Market. For the past 30 consecutive business days, the company's common stock has closed below the required $1.00 per share threshold. While companies typically have 180 days to rectify such deficiencies, Windtree is under a Discretionary Panel Monitor until March 2026. This situation arises as the company has conducted two reverse stock splits in the last two years, totaling a ratio of over 250 to one. Windtree plans to request a hearing before a Nasdaq Hearings Panel by June 25, 2025, which will temporarily stay any suspension or delisting actions. However, there is no guarantee that the company will be granted an extension or regain compliance. Currently, Windtree's stock continues to trade under the symbol \"WINT.\"","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"WINT":"Windtree Therapeutics, Inc.","BK4139":"生物科技"},"translate_title":"由于投标价格不足，Windtree Therapeutics可能面临纳斯达克退市","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"WINT":0.9},"content_text":"Windtree Therapeutics Faces Potential Nasdaq Delisting Due to Bid Price Deficiency\n    \n\n        Windtree Therapeutics Inc. has announced receiving a deficiency letter from the Nasdaq Listing Qualifications Department regarding its failure to meet the minimum bid price requirement for continued listing on the Nasdaq Capital Market. For the past 30 consecutive business days, the company's common stock has closed below the required $1.00 per share threshold. While companies typically have 180 days to rectify such deficiencies, Windtree is under a Discretionary Panel Monitor until March 2026. This situation arises as the company has conducted two reverse stock splits in the last two years, totaling a ratio of over 250 to one. Windtree plans to request a hearing before a Nasdaq Hearings Panel by June 25, 2025, which will temporarily stay any suspension or delisting actions. However, there is no guarantee that the company will be granted an extension or regain compliance. Currently, Windtree's stock continues to trade under the symbol \"WINT.\"\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Windtree Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001437749-25-020949), on June 20, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}